---
layout: post
title: "Bristol Myers Products Inc.; Withdrawal of Approval of a New Drug Application for BUFFERIN (Aspirin) Tablets"
date: 2026-02-05 18:56:11 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-15454
original_published: 2023-07-21 00:00:00 +0000
significance: 8.00
---

# Bristol Myers Products Inc.; Withdrawal of Approval of a New Drug Application for BUFFERIN (Aspirin) Tablets

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** July 21, 2023 00:00 UTC
**Document Number:** 2023-15454

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for BUFFERIN (aspirin) tablets. The basis for the withdrawal is that the holder of the NDA has repeatedly failed to file required annual reports for this NDA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/07/21/2023-15454/bristol-myers-products-inc-withdrawal-of-approval-of-a-new-drug-application-for-bufferin-aspirin)
- API: https://www.federalregister.gov/api/v1/documents/2023-15454

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
